Consensus development conference on pramlintide in the management of type 1 and type 2 diabetesHIRSCH, Irl B; BLONDE, Lawrence; BUSE, John et al.Diabetes (New York, NY). 2006, Vol JUN, pp 1-13, issn 0012-1797, 13 p., HSArticle

Pramlintide contre le diabète = Pramlintide and diabeteThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 13, pp 67-69, issn 0253-8512, 3 p.Article

Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitusNOGID, Anna; PHAM, David Q.Pharmacotherapy. 2006, Vol 26, Num 11, pp 1626-1640, issn 0277-0008, 15 p.Article

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing studyMAGGS, David G; FINEMAN, Mark; KORNSTEIN, Jonathan et al.Diabetes/metabolism research and reviews (Print). 2004, Vol 20, Num 1, pp 55-60, issn 1520-7552, 6 p.Article

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumpsLEVETAN, Claresa; WANT, Laura L; HENRY, Robert R et al.Diabetes care. 2003, Vol 26, Num 1, pp 1-8, issn 0149-5992, 8 p.Article

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing studyWEYER, Christian; GOTTLIEB, Alan; KIM, Dennis D et al.Diabetes care. 2003, Vol 26, Num 11, pp 3074-3079, issn 0149-5992, 6 p.Article

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesWHITEHOUSE, Fred; KRUGER, Davida F; FINEMAN, Mark et al.Diabetes care. 2002, Vol 25, Num 4, pp 724-730, issn 0149-5992Article

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic controlWEYER, C; MAGGS, D. G; YOUNG, A. A et al.Current pharmaceutical design. 2001, Vol 7, Num 14, pp 1353-1373, issn 1381-6128Article

Amylin activates distributed CNS nuclei to control energy balanceMIETLICKI-BAASE, Elizabeth G; HAYES, Matthew R.Physiology & behavior. 2014, Vol 136, pp 39-46, issn 0031-9384, 8 p.Conference Paper

The Role of Pramlintide for Weight LossDUNICAN, Kaelen C; ADAMS, Nicole M; DESILETS, Alicia R et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 3, pp 538-545, issn 1060-0280, 8 p.Article

A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 DiabetesKISHIYAMA, Christopher M; BURDICK, Patricia L; COBRY, Erin C et al.Pediatrics (Evanston). 2009, Vol 124, Num 5, pp 1344-1347, issn 0031-4005, 4 p.Article

New Drugs for Type 2 Diabetes Mellitus : What is their Place in Therapy?KRENTZ, Andrew J; PATEL, Mayank B; BAILEY, Clifford J et al.Drugs (Basel). 2008, Vol 68, Num 15, pp 2131-2162, issn 0012-6667, 32 p.Article

The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 DiabetesRODRIGUEZ, Luisa M; MASON, Kimberly J; HAYMOND, Morey W et al.Pediatric research. 2007, Vol 62, Num 6, pp 746-749, issn 0031-3998, 4 p.Article

Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug productHEKMAN, C; DEMOND, W; DIXIT, T et al.Pharmaceutical research. 1998, Vol 15, Num 4, pp 650-659, issn 0724-8741Article

Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 DiabetesWEINZIMER, Stuart A; SHERR, Jennifer L; CENGIZ, Eda et al.Diabetes care. 2012, Vol 35, Num 10, pp 1994-1999, issn 0149-5992, 6 p.Article

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with Type 1 diabetesMARRERO, David G; CREAN, John; BEI ZHANG et al.Diabetes care. 2007, Vol 30, Num 2, pp 210-216, issn 0149-5992, 7 p.Article

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trialRATNER, R. E; DICKEY, R; FINEMAN, M et al.Diabetic medicine. 2004, Vol 21, Num 11, pp 1204-1212, issn 0742-3071, 9 p.Article

Effect of pramlintide on A_1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysisMAGGS, D; SHEN, L; STROBEL, S et al.Metabolism, clinical and experimental. 2003, Vol 52, Num 12, pp 1638-1642, issn 0026-0495, 5 p.Article

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)HILES, Richard A; BAWDON, Roger E; PETRELLA, Ezio M et al.Human & experimental toxicology. 2003, Vol 22, Num 12, pp 623-628, issn 0960-3271, 6 p.Article

Pramlintide, an amylin analog, selectively delays gastric emptying : potential role of vagal inhibitionSAMSOM, M; SZARKA, L. A; CAMILLERI, M et al.American journal of physiology. Gastrointestinal and liver physiology. 2000, Vol 41, Num 6, pp G946-G951, issn 0193-1857Article

Drug therapy of postprandial hyperglycaemiaMOORADIAN, A. D; THURMAN, J. E.Drugs (Basel). 1999, Vol 57, Num 1, pp 19-29, issn 0012-6667Article

Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 DiabetesELKIND-HIRSCH, Karen; BUTLER, William J; BHUSHAN, Madhu et al.Diabetes care. 2008, Vol 31, Num 1, pp 39-40, issn 0149-5992, 2 p.Article

A Biophysical Characterization of the Peptide Drug Pramlintide (AC137) Using Empirical Phase DiagramsNONOYAMA, Akihisa; LAURENCE, Jennifer S; GARRIQUES, Liza et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 7, pp 2552-2567, issn 0022-3549, 16 p.Article

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects : a 6-wk translational research studySMITH, Steven R; BLUNDELL, John E; BUMS, Colleen et al.American journal of physiology. Endocrinology and metabolism. 2007, Vol 56, Num 2, issn 0193-1849, E620-E626Article

Diabetes : Assessing the pipelineLEBOVITZ, Harold.Atherosclerosis. Supplement (Amsterdam). 2006, Vol 7, Num 1, pp 43-49, issn 1567-5688, 7 p.Article